• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

COVID-19 Vaccination in Children Ages 5 to 11: Safety, Immunogenicity, and Efficacy Results

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Walter et al. (NEJM, 2021) report on the safety and efficacy outcomes of a phase 2-3 trials of BNT162b2 (Pfizer) COVID-19 vaccine in children ages 5 to 11

METHODS:

  • Phase 1 dose-finding study, and ongoing phase 2 to 3 randomized trial
  • Participants
    • Children 6 months to 11 years of age | Data presented for children ages 5 to 11 years old
  • Intervention
    • Phase 1
      • 10 μg, 20 μg, or 30 μg of BNT162b2 vaccine
    • Phase 2 to 3
      • Two doses of vaccine administered 21 days apart
        • Dose level identified during the open-label phase 1 study
      • Placebo
  • Primary outcomes
    • Immune response 1 month after second dose
    • Vaccine efficacy against COVID-19 ≥7 days after second dose

RESULTS:

  • Phase 1 study: 48 children
    • A dose level of 10 μg was selected based on reactogenicity and immunogenicity
  • Phase 2 to 3 trial: 2268 children
    • Vaccine: 1517 children | Placebo: 751 children
    • Median follow-up up was 2.3 months at data cutoff
  • Safety
    • The vaccine had a favorable safety profile in this age group
      • There were no vaccine-related serious adverse events
  • Immunogenicity
    • Geometric mean ratio of SARS-CoV-2 neutralizing titers one month after second dose
      • 5- to 11-year-olds compared to 16- to 25-year-olds
      • 1.04 (95% CI, 0.93 to 1.18)
    • This ratio met the prespecified immunogenicity success criterion
  • Efficacy against COVID-19
    • Incidence of COVID-19 onset ≥7 days after the second dose
      • Vaccine group: 3 individuals
      • Placebo group: 16 individuals
    • Vaccine efficacy: 90.7% (95% CI, 67.7 to 98.3)

CONCLUSION:

  • The Pfizer vaccination regimen in children ages 5 to 11 was set at two 10 μg shots 21 days apart based on reactogenicity and immunogenicity data in this age group
  • This vaccination regimen was safe, and immunogenicity was comparable to 16 to 25 year cohort
  • Vaccine efficacy against COVID-19 for children aged 5 to 11 was 90.7%
  • The authors state

The data reported herein support vaccination of 5-to-11-year-old children with two 10-μg doses of the BNT162b2 vaccine

Evaluation of BNT162b2 in younger children is ongoing

Learn More – Primary Sources:

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

Safety and Efficacy Data of BNT162b2 COVID-19 Vaccine
Safety and Efficacy of Pfizer-BioNTech COVID-19 Vaccine in Adolescents

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site